NEW YORK, May 4 – Large Scale Biology and Illumina both adopted stockholder rights plans Friday, in a preemptive effort to head off hostile takeover attempts, the companies said.

The actions follow similar moves by several other companies in the last several weeks, and are “usually a clue that things are getting too cheap in the markets,” said Franklin Berger, an analyst with JP Morgan H&Q in New York.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.